NEW

Study Confirms Surfacide UV-C Kills SARS-CoV-2

A recent peer-reviewed study in the Journal of Clinical Anesthesia* found the Surfacide Helios® System UV-C technology is nearly 95% effective in preventing SARS CoV-2 in patient environments. This is the first clinical study that evaluates the use of UV-C in...

AORN Recommends Nasal Decolonization with PVP-I

The Association of periOperative Registered Nurses (AORN) has announced its annual updated recommendations on the "Guideline for Preoperative Skin Antisepsis," to assist health care professionals in navigating risk-based decisions for developing preoperative...

New AAAHC Quality Roadmap Probes Data, Highlights Surveyor Insights

On June 16, AAAHC released its 2021 Quality Roadmap, a comprehensive analysis of data from more than 1,120 accreditation surveys conducted in 2020.

RSIP Vision Reveals New Module

RSIP Vision has announced its new surgical workflow analysis technology, which can intelligently identify each separate stage of a surgical procedure and label them accordingly throughout the duration of the procedure.

AccessClosure Launches the Next-Generation Mynx Ace Vascular Closure Device

accessclosure-1AccessClosure Inc. has commercially launched its Mynx Ace Vascular Closure Device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites. The device joins the pioneering line of Mynx extravascular products that help care teams reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures. The commercial launch was announced as part of the annual meeting of the American College of Cardiology.

“We are proud of the advantages Mynx Ace offers to femoral closure,” said Gregory D. Casciaro, president and CEO of AccessClosure Inc. “Our continual drive toward innovations that provide physicians with outstanding products to improve patient care has allowed us to develop a closure device that provides consistent results, while continuing to offer the safety and security that has become synonymous with the Mynx name.”

Mynx closure devices are designed for patient comfort by providing gentle vascular closure without the use of cinching, sutures, or metal implants to enhance patient satisfaction and keep physicians on the leading edge of patient care. With Mynx Ace, physicians can consistently close femoral artery access sites through a simple, three-step deployment system. The Mynx Ace system uses AccessClosure’s proprietary Grip Technology. Grip Technology employs an extravascular sealant that actively adheres to the artery for safe and secure mechanical closure and dissolves within 30 days, leaving nothing behind in the healed vessel.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X